Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC
Clinical trial NCT07549100 · RECRUITING
Trial details
- NCT number
- NCT07549100
- Sponsor
- Shandong Provincial Hospital
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2023-05-15
- Primary completion
- 2027-12-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.